<DOC>
	<DOCNO>NCT01596062</DOCNO>
	<brief_summary>The aim study extensively study level CD25-Receptors saturation expression obtain 2 different dos Simulect® combination Neoral® ( i.e demonstrate saturation expression vary accord dose Simulect® give ) , study level CD25-Receptors saturation without Neoral® compare data Neoral® . It conduct low risk de novo adult renal transplant recipient 12 week post-transplant , receive either cumulative dose 40 80 mg Simulect® combination Neoral® , cumulative dose 80 mg Simulect® calcineurin inhibitor free immunosuppressant therapy .</brief_summary>
	<brief_title>Pharmacodynamics , Efficacy Safety Basiliximab 40 80 mg Combination With Ciclosporine Microemulsion Everolimus , Adult Low Risk de Novo Renal Transplant Recipients ( IDEALE Study )</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Patients receive primary renal graft decease living , relate unrelated donor require basiliximab induction therapy Cold ischemia time &lt; 30 hour Exclusion ( Non inclusion ) criterion : Patients undergo multiorgan transplantation , include kidney , previously undergone organ transplantation , include renal transplantation Patients receive graft nonheartbeating donor ABO incompatible graft positive T cell crossmatch Patients receive graft expand criterion donor accord UNOS definition ( donor old 60 year donor age 50 60 year presence least 2 follow factor : hypertension , serum creatinine concentration ≥ 132 µmol/mL , cardiovascular cause death ) Positive antiHLA antibody ( Luminex ) prior transplantation Patients whose original renal disease primary focal segmental hyalinosis related atypical hemolytic uremic syndrome EBVnegative patient receive graft EBVpositive donor ( EBV D+R ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Basiliximab</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>CNI-free</keyword>
	<keyword>everolimus</keyword>
</DOC>